AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

GPCR · NASDAQ · Biotechnology

Structure Therapeutics (ADR)

Develops oral small-molecule medicines for metabolic, cardiovascular, and pulmonary conditions.

$47.37

After-hours close−0.10 (−0.21%)

At close$47.47(−3.56%)

Something off on this page? Send us feedback.

Profile

Structure Therapeutics Inc.GPCRHealth Care

Develops investigational oral small-molecule medicines against GPCR targets. Its most advanced program, aleniglipron, targets obesity, while other candidates address metabolic, cardiovascular, and pulmonary disorders.

Develops investigational oral small-molecule medicines through structure-based discovery and computational chemistry, focused on GPCR targets. Aleniglipron, an oral nonpeptide GLP-1 receptor agonist for obesity, is its most advanced candidate.

Headquartered in South San Francisco, with R&D operations in Shanghai, it also develops ACCG-2671, ANPA-0073, LTSE-2578, and ACCG-3535 for metabolic, cardiovascular, and pulmonary disorders. It has no commercial-product sales or product revenue and remains an investigational clinical-development business today.

Progress depends on clinical-study timing and outcomes, regulatory filings and approvals, third-party service providers, intellectual-property protection, manufacturing and commercialization planning, and continued financing.

Company facts

CEORaymond Stevens

ListedFeb 3, 2023

ExchangeNASDAQ

HeadquartersSouth San Francisco, CA

CountryUnited States

Employees220

CIK0001888886

ISINUS86366E1064

Key statistics

Market cap$2.73B

EPS (ttm)−$3.03

P/E (ttm)−15.63

ROE-16.9%

P/B2.54

P/S0.00

Dividend yield—

Beta0.85vs XLV −0.05

Year to date −30.3% · Average volume (30d) 555.1K

Analysts

Price target, next 12 months$111.00+134.3%Median of 14 analysts · vs the Aug 28 close

ConsensusBuy14 of 14 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $47.37

High$145.00+206.1%

Median$111.00+134.3%

Low$70.00+47.8%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Aug 7, 2026	Canaccord Genuity	Target		$101	$111
Jun 11, 2026	H.C. Wainwright	Target		$90	$70
Apr 27, 2026	Canaccord Genuity	Target			$101
Mar 17, 2026	BMO Capital	Target		$100	$145
Jan 20, 2026	Guggenheim	Reiterate	Buy		$140

Earnings

EPS

Estimate−$0.32

ReportedDue Nov 5, 2026

Revenue

Estimate$45.5M

ReportedDue Nov 5, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 6, 2026Q2 FY26	−$0.39	−$0.49	−25.6%	—	—	—	+0.99%
May 7, 2026Q1 FY26	−$0.39	−$0.35	+10.3%	$11.1M	—	—	−0.13%
Feb 26, 2026Q4 FY25	−$0.35	−$0.49	−40.0%	$9.2M	—	—	−2.73%
Nov 6, 2025Q3 FY25	−$0.36	−$0.37	−2.8%	—	—	—	−1.88%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$0	$0	$0	$0	$0	$0
Gross profit	$0	$0	$0	$0	−$1.2M	$0
Operating income	−$56.3M	−$70.5M	−$73.8M	$24.0M	−$89.6M	−$118.6M
Net income	−$46.8M	−$61.7M	−$65.7M	$33.0M	−$76.2M	−$106.2M
Diluted EPS	−$0.81	−$1.08	−$1.11	$0.60	−$1.05	−$1.47
Gross margin	—	—	—	—	—	—
Operating margin	—	—	—	—	—	—

Fiscal years (4-quarter sums)FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0

Balance sheet, Jun 30, 2026Cash & short-term investments $1.34B · Total debt $6.2M · Total assets $1.43B · Shareholders' equity $1.35B

Dividends

No dividends on record.

Ownership

Institutions 115.89%Insiders —

Shares outstanding 57.57M · Float 54.73M · 95.1% free float

Insiders — filings are in the shares behind the receipt.

This listing is a depositary receipt and the Form 4 positions here are filed in the shares behind it, a different unit from the share count and in a ratio the filings never state, so no insider percentage is shown.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
FMR LLC	8.40M	14.60%	13F	May 15, 2026
Wellington Management Group LLP	7.26M	12.61%	13F	May 15, 2026
Avoro Capital Advisors LLC	6.56M	11.39%	13F	May 15, 2026
Janus Henderson Group PLC	5.35M	9.30%	13F	May 18, 2026
Deep Track Capital, LP	4.28M	7.43%	13F	May 15, 2026

Insider tradesForm 4

Date	Insider	Role	Shares
Aug 18, 2026	Xichen Lin	officer: CHIEF SCIENTIFIC OFFICER	−3,939
Aug 4, 2026	Xichen Lin	officer: CHIEF SCIENTIFIC OFFICER	−3,939
Jul 22, 2026	FMR LLC	10 percent owner, other: See Remark 1	−17,452
Jul 14, 2026	Xichen Lin	officer: CHIEF SCIENTIFIC OFFICER	−7,878
Jun 25, 2026	Xichen Lin	officer: CHIEF SCIENTIFIC OFFICER	−7,878